Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer

Data from CaPSURE™

Authors

  • David M. Latini Ph.D.,

    Corresponding author
    1. Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
    • Department of Urology, University of California San Francisco, Box 1798, San Francisco, CA 94143–1798
    Search for more papers by this author
    • Fax: (415) 353–7674

  • Eric P. Elkin M.P.H.,

    1. Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
    Search for more papers by this author
  • Matthew R. Cooperberg M.D., M.P.H.,

    1. Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
    Search for more papers by this author
  • Natalia Sadetsky M.D. M.P.H.,

    1. Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
    Search for more papers by this author
  • Janeen DuChane Ph.D.,

    1. TAP Pharmaceutical Products Inc., Lake Forest, Illinois
    Search for more papers by this author
  • Peter R. Carroll M.D.,

    1. Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
    Search for more papers by this author
  • CaPSURE™ Investigators

    Search for more papers by this author
    • Current CaPSURE investigators are: Peter R. Carroll, M.D. (University of California, San Francisco, San Francisco, CA), James S. Cochran, M.D. (Urology Clinics of North Texas, Dallas, TX), Christopher J. Kane, M.D. (Veterans Administration Medical Center, San Francisco, CA), Donald P. Finnerty, M.D. (PAPP Clinic, Newnan, GA), Eugene V. Kramolowsky, M.D. (The Virginia Urology Center, Richmond, VA), Robert M. Segaul, M.D. (Urology Associates of West Broward Belle Terre, Sunrise, FL), Paul Sieber, M.D. (Urological Associates of Lancaster, Lancaster, PA), Stanley A. Brosman, M.D. (Pacific Clinical Research, Santa Monica, CA), Lynn W. Conrad, M.D. (Urology Center of the South PC, Memphis, TN), Joseph N. Macaluso Jr., M.D., (Urologic Institute of New Orleans, Gretna, LA), Michael Flanagan, M.D. (Urology Specialists, Waterbury, CT), Jeffrey K. Cohen, M.D. (Triangle Urology Group, Pittsburgh, PA), Jerrold Sharkey, M.D. (Urology Health Center, New Port Richey, FL), Thomas W. Coleman, M.D. (Mobile Urology Group, Mobile, AL), Elliott C. Silbar, M.D. (Clinic of Urology, Milwaukee, WI), Paul S. Ray, D.O. (Cook County Hospital, Chicago, IL), David Noyes, M.D. (Berkshire Urological Associates P.C., Pittsfield, MA), Mohammed Mostafavi, M.D. (Urology Group of Western New England, Springfield, MA), Louis Keeler III, M.D. (Center for Urologic Care, Voorhees, NJ), James Gottesman, M.D. (Seattle Urological, Seattle, WA), Bhupendra M. Tolia, M.D. (Associated Advanced Adult & Pediatric Urology, Bronx, NY), W. Lamar Weems, M.D. (Mississippi Urology, Jackson, MS), Glen Wells, M.D. (Alabama Urology, Birmingham, AL), Richard J. Kahnoski, M.D. (Michigan Medical, Grand Rapids, MI), Sheldon J. Freedman, M.D. (Las Vegas, NV), Randil Clark, M.D. (North Idaho Urology, Coeur D'Alene, ID), David Penson, M.D., M.P.H. (Veterans Administration Puget Sound HCS, Seattle, WA), Mark Austenfeld, M.D. (Kansas City Urology Care, Kansas City, MO), Henri P. Lanctin, M.D. (Adult & Pediatric Urology, St. Cloud, MN), J. Brantley Thrasher, M.D. (University of Kansas, Kansas City, KS), and David W. Bowyer, M.D. (Snake River Urology, Twin Falls, ID).

    • Former CaPSURE investigators are: John Forrest, M.D. (1995–1999, Urologic Specialists of Oklahoma, Tulsa, OK), William Schmeid, M.D. (1995– 1999, Metro Urology, Jeffersonville, IN), Glen Brunk, M.D. (1995– 1999, Urology of Indiana, Indianapolis, IN), Jay Young, M.D. (1995–2001, South Orange County Medical Research Center, Laguna Woods, CA), Gary Katz, M.D. (1996–2000, Medical College of Virginia and Veterans Administration Medical Center, Richmond, VA), Stacy J. Childs, M.D. (1999–2000, Cheyenne Urological, Cheyenne, WY), Kevin Tomera, M.D. (1999–2001, Alaska Urological Associates, Anchorage, AK), Clayton Hudnall, M.D. (1995–2002, Urology San Antonio Research, San Antonio, TX).


Abstract

BACKGROUND

Few studies of ethnicity and prostate cancer have included Latino men in analyses of baseline clinical characteristics, treatment selection, and disease-free survival (DFS). The present study examines the impact of Latino ethnicity on these parameters in a large, multiinstitutional database of men with prostate cancer.

METHODS

We compared baseline disease characteristics and clinical outcomes for Latino (N = 138), non-Latino White (NLW, N = 5619), and African-American (AA, N = 608) men with localized prostate cancer by using chi-square and ANOVA for baseline variables and survival analysis to examine differences in time to recurrence.

RESULTS

Latino men resembled AA men more than NLW on sociodemographic characteristics. AA men had higher Gleason scores and prostate-specific antigen (PSA) at diagnosis than Latino or NLW men (both P < 0.01). 10% of both Latino and AA men presented with advanced disease (T3b/T4/N+/M+) versus 4% of NLW (P < 0.01). Latino men did not receive different treatments than NLW or AA men after controlling for clinical and demographic factors; however, AA men were more likely to receive external beam radiation (OR = 1.51, 95% confidence interval [CI] = 0.99–2.31) and hormone treatment (OR = 1.56, 95% CI = 1.05–2.32) then NLW men. For prostatectomy patients, 3-year actuarial DFS rates were 83% for NLW men and 86% for Latino men versus 69% for AA men (P < 0.01). After controlling for clinical and sociodemographic variables, AA men were somewhat more likely than NLW to experience disease recurrence after radical prostatectomy (RP) (HR = 1.38, 95% CI = 0.98–1.94, P = 0.06).

CONCLUSIONS

Latinos are more similar to African Americans on sociodemographic characteristics but more similar to NLW on clinical presentation, treatments received, and DFS. Cancer 2006. © 2006 American Cancer Society.

Ancillary